Ipamorelin: Molecular Characterization and Receptor Pharmacology — A Research Reference

The sequence is aminoisobutyryl-histidyl-D-2-naphthylalanyl-D-phenylalanyl-lysinamide, conventionally written Aib-His-D-2-Nal-D-Phe-Lys-NH2. Its molecular weight is approximately 712 daltons and its molecular formula is C38H49N9O5.

Position one is aminoisobutyric acid, not one of the twenty proteinogenic amino acids: it carries two methyl groups on the alpha carbon rather than a hydrogen and a side chain, making it achiral and conformationally restrictive. Residues of this kind constrain the backbone angles a peptide can adopt, favouring particular turn geometries, and they are poor substrates for aminopeptidases, which expect a conventional amino terminus.

Positions three and four are D-amino acids: D-2-naphthylalanine and D-phenylalanine. Natural proteins are built almost exclusively from L-amino acids and proteases have evolved to act on that stereochemistry, so inverting a residue at a cleavage-prone position confers resistance. The 2-naphthylalanine side chain is also larger than any natural aromatic residue, extending the phenyl ring of phenylalanine into a fused two-ring system.

The carboxyl terminus is an amide rather than a free acid. C-terminal amidation is common among bioactive peptides and removes the negative charge a free carboxylate would carry at neutral pH.

The Target Receptor

The growth hormone secretagogue receptor, GHS-R1a, is a class A G-protein-coupled receptor. It was identified in 1996 by expression cloning from pituitary and hypothalamic tissue, using synthetic secretagogues as the screening ligands — an unusual sequence of events in which the receptor was found before its endogenous ligand [2]. That ligand, ghrelin, was characterized three years later as an acylated 28-residue peptide bearing an octanoyl group on a serine side chain, the acyl modification being required for receptor engagement [3].

Unlike the class B receptors engaged by GHRH-family analogues, GHS-R1a is a class A receptor with a compact transmembrane binding pocket rather than a large extracellular capture domain. Its ligands are correspondingly small: a five-residue synthetic peptide is a plausible agonist here in a way it would not be at a class B receptor, where peptide ligands typically run to thirty residues or more.

A crystal structure of the receptor in an antagonist-bound state subsequently resolved the binding pocket architecture and indicated how the acylated endogenous ligand is likely accommodated [4]. That structure is the framework in which synthetic secretagogue binding is now interpreted.

Selectivity

The property that distinguished ipamorelin at introduction was selectivity within this receptor family: reported in-vitro characterization described engagement at GHS-R1a without the cross-reactivity at adjacent receptors shown by earlier secretagogues of the same generation [1]. For receptor-pharmacology work that makes it a comparatively clean tool compound for the target, and it is the reason the molecule remains a reference ligand in this class.

Mass spectrometry confirms the intact molecular mass near 712 daltons, and for this compound the measurement carries a specific diagnostic value. If the C-terminal amide failed to form during synthesis, the resulting free-acid impurity is heavier than the target by approximately one dalton — a small but defined difference, detectable given adequate resolving power. A certificate reporting a mass rounded to whole numbers cannot exclude it.

Reversed-phase HPLC resolves the main peak from related substances and yields the purity figure. The characteristic related substances here are diastereomers: the D-configured residues at positions three and four can invert during synthesis to the L form, producing compounds of identical molecular mass that mass spectrometry cannot distinguish at all. They separate chromatographically, which is precisely why the two methods are run in combination rather than either being treated as sufficient on its own.

Amino acid analysis is less informative for this compound than for conventional sequences, since hydrolysis does not readily distinguish D from L residues and aminoisobutyric acid requires the method to be configured for it. The chromatogram carries the useful information here.

Net peptide content accounts for counter-ions and residual water, determining how much peptide a nominal milligram figure represents.

Sealed lyophilized material is stable at ambient temperature for the duration of transit and requires no cold chain in shipping. On receipt, vials are refrigerated and kept out of direct light.

Reconstituted material is held refrigerated and used within the window the receiving facility's protocols specify, and repeated freeze-thaw cycling is avoided. Solutions are short-lived relative to the lyophilized form.

By composition this is a robust molecule. The sequence contains no cysteine and no methionine, removing the two most common oxidation routes, and no asparagine or glutamine, removing deamidation as a degradation pathway. The residues warranting attention are the aromatics — naphthylalanine, phenylalanine, and the imidazole of histidine — which is reason enough to keep solutions out of direct light. Five residues present very little surface for aggregation, so the material dissolves readily and vigorous agitation is unnecessary.

The substitutions that resist enzymatic cleavage in biological media confer no advantage against the physical routes that govern storage.

Ipamorelin is an investigational compound. It has not been approved by the FDA or any other regulatory authority, and no manufacturing, labeling, or quality standards for an approved product apply to it. Research material is sold strictly for laboratory research use; it must not be administered to humans or animals. Researchers are responsible for compliance with all institutional and jurisdictional requirements governing research chemicals.

Each batch of research-grade ipamorelin is accompanied by an independent certificate of analysis specific to that lot.

Ipamorelin is a synthetic pentapeptide of approximately 712 daltons — Aib-His-D-2-Nal-D-Phe-Lys-NH2 — carrying three non-proteinogenic residues and an amidated C-terminus. It is characterized against GHS-R1a, a class A G-protein-coupled receptor identified by expression cloning before its endogenous acylated ligand was known and subsequently resolved structurally, and was described on introduction as the first selective compound of its secretagogue class. Analytical verification rests on mass confirmation of the amidated terminus, chromatographic resolution of diastereomers invisible to mass measurement, and batch-specific net peptide content.